Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 69.09M P/E - EPS this Y 25.60% Ern Qtrly Grth -
Income -19.92M Forward P/E -4.02 EPS next Y 18.00% 50D Avg Chg 34.00%
Sales 6.21M PEG - EPS past 5Y - 200D Avg Chg 120.00%
Dividend N/A Price/Book 2.02 EPS next 5Y - 52W High Chg -13.00%
Recommedations 2.00 Quick Ratio 6.89 Shares Outstanding 23.42M 52W Low Chg 302.00%
Insider Own 20.19% ROA -36.56% Shares Float 10.97M Beta 0.89
Inst Own 44.18% ROE -70.01% Shares Shorted/Prior 88.91K/84.44K Price 3.26
Gross Margin 29.12% Profit Margin - Avg. Volume 135,304 Target Price 4.50
Oper. Margin -329.81% Earnings Date May 14 Volume 30,952 Change -2.40%
About InspireMD Inc.

InspireMD, Inc., a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions. InspireMD, Inc. has a strategic agreement with Jacobs Institute to execute an early feasibility study of CGuard Prime for the treatment of acute stroke patients with tandem lesions. The company sells its products through local distribution partners. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel.

InspireMD Inc. News
04/03/24 InspireMD to Present at the 23rd Annual Needham Virtual Healthcare Conference
03/31/24 InspireMD's (NASDAQ:NSPR) investors will be pleased with their solid 110% return over the last year
03/26/24 InspireMD Announces Abstract of One-Year Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial Accepted for Presentation at LINC 2024
03/07/24 InspireMD, Inc. (NASDAQ:NSPR) Q4 2023 Earnings Call Transcript
03/06/24 InspireMD Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
02/28/24 InspireMD to Report Fourth Quarter and Full-Year 2023 Financial Results and Provide Corporate Business Update on Wednesday, March 6th
02/12/24 InspireMD Appoints Principal Investigators for C-GUARDIANS II Clinical Trial of the SwitchGuard™ Neuroprotection System
01/31/24 InspireMD Receives CE Mark Recertification Under EU’s New Medical Device Regulation (MDR) Regulatory Framework
01/23/24 We're Hopeful That InspireMD (NASDAQ:NSPR) Will Use Its Cash Wisely
01/03/24 InspireMD Announces Appointment of Medical Technology Executive Pete Ligotti as Executive Vice President and General Manager of North America
12/20/23 InspireMD Announces Issuance of Key U.S. Patent Covering Its SwitchGuard™ Neuroprotection System
12/06/23 InspireMD's Gary Roubin Acquires 13% More Stock
11/27/23 InspireMD Announces Strategic Agreement with Jacobs Institute to Execute Early Feasibility Study of CGuard EPS for the Treatment of Acute Stroke Patients with Tandem Lesions
11/07/23 InspireMD, Inc. (NASDAQ:NSPR) Q3 2023 Earnings Call Transcript
11/06/23 InspireMD Inc (NSPR) Reports Q3 2023 Financial Results: CGuard EPS Revenue Increases by 9% ...
11/06/23 InspireMD Reports Third Quarter 2023 Financial Results and Provides Business Update
11/02/23 InspireMD to Participate in Upcoming November Investor Conferences
11/01/23 InspireMD Presents Positive 30-Day Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial at VIVA23
10/30/23 InspireMD to Report Third Quarter 2023 Financial Results and Provide Corporate Business Update on Monday, November 6th
10/23/23 InspireMD's (NASDAQ:NSPR) investors will be pleased with their impressive 179% return over the last year
NSPR Chatroom

User Image JBinLB Posted - 5 hours ago

$NSPR they must want to do another r/s to get their Israeli friends in cheap. Just ask LoyalShark he knows

User Image SWilder Posted - 8 hours ago

$NSPR good vid talking about NSPR https://youtu.be/5UUkztkpTnk?si=TdqG9IAAhUPPQm0F

User Image GiveHerTheDD Posted - 14 hours ago

$NSPR New investor presentation. No substantial updates. They just clarified some things better and updated numbers. New presentation: https://www.inspiremd.com/en/wp-content/uploads/NSPR-Investor-Presentation-April-2024-final.pdf

User Image GiveHerTheDD Posted - 1 day ago

$NSPR Suspected CGuard and NGuard presentations at ICCA Stroke conference in Frankfurt, Germany on June 21-22, 2024. Friday / 08:35 – 10:35 CEST CAROTID AND VERTEBRAL STENTING: STEP BY STEP Title: Optimal medical therapy for Carotid artery stenosis Presenter: Piotr Musialek Product: CGuard Friday / 13:40 – 14:40 CEST CAROTID STENTING IN IMMINENT AND ACUTE STROKE Title: What do we know about mesh stents in acute carotid stroke Presenter: Piotr Musialek Product: CGuard / NGuard Saturday / 08:30 - 09:30 CEST ACUTE STROKE: DEVICES Title: New technology Presenter: Adnan Siddiqui Product: NGuard Saturday / 13:05 – 14:20 CEST ACUTE STROKE: CURRENT STATE OF THE ART Title: Tandem occlusion – case example Presenter: Adnan Siddiqui Product: NGuard Source: https://iccaonline.org/scientific-program/

User Image GiveHerTheDD Posted - 1 day ago

$NSPR Need you to advise on something @LoyalShark Marshall Wace has stake in NSPR under MW XO Health Innovations Fund, which is a buyout fund. Two question: 1. Do buyout funds always try to obtain a majority stake in a company or should we think nothing of it? 2. Given that Marvin and Craig just amended their contracts with golden parachutes, do we expect Marshall Wace to take over a majority shares since they led the private financing and have holdings under a buyout fund? They posted the number of share beneficially owned by each party for within 60 days of April 18, 2024 on their annual shareholder meeting document: https://fintel.io/doc/sec-inspiremd-inc-1433607-def-14a-2024-april-18-19831-3850 MW XO Health Innovations will own $26,037,498 shares, but all together, the institutions will own over 90% of the outstanding shares according to the numbers posted.

User Image GiveHerTheDD Posted - 1 day ago

$NSPR The month of May has historically been when news ramps up and the stock moves. Maybe management will stop using CGuard trial news as their only crutch to stand up and finally give updates on something else? • China distribution? • NGuard clinical trial? • CGuard Prime commercialization in EU? All things above mentioned and planned for 2023 and not achieved. What honestly is the hold-up on progressing the business? The CGuard trial is enrolled and complete. What are your employees doing now that it is over? So confused.

User Image LoyalShark Posted - 2 days ago

@SWilder @JBinLB $NSPR Had the same question. BUT it appears we are down simply because no one knows we exist.

User Image SWilder Posted - 2 days ago

@JBinLB I was just wondering if Isr stocks were down today but I see the biggest ones MBLY CHKP TEVA NICE are all up. I just started following $NSPR so I don't know the latest but today's drop doesn't seem to be Israel news specific

User Image JBinLB Posted - 2 days ago

$NSPR Israeli junk

User Image Meterdoc Posted - 2 days ago

$NSPR Told ya, always some unanticipated BS lurking somewhere. Still in this turd.

User Image mag_x Posted - 2 days ago

$NSPR I definitely don't know anything about investing... hours reading documents. Hours understanding what's going on. Hours studying the companies. And still... I always make the bad calls Anyways... almost all in. I can't be that wrong with this. Or they are lying about their stents....

User Image LoyalShark Posted - 2 days ago

$NSPR Charts speak volumes. This is NOT a bullish chart at this point. Since January -- a disaster. Looking for a reversal pattern.

User Image LoyalShark Posted - 2 days ago

$NSPR To allow this this to melt down as it has since announcing incredible results back in October is criminal. This one is 100% on Marvin and Shore. They do not understand how to create an expected value within the markets. InspireMD's IR firm is amongst the worst I have ever seen. It is beyond terrible. Going to take advantage of it when a bottom is put in. Waiting.

User Image GiveHerTheDD Posted - 2 days ago

$NSPR Events page updated significantly. No holds leading to the LINC presentation of 1-year CGuard FDA trial data release. Source: https://www.inspiremd.com/en/events/

User Image Marquisdemod Posted - 4 days ago

$NSPR finally gave up and cut my loses, been here since 2021. Byeeeee terrible company!

User Image RedDogSailor Posted - 5 days ago

$NSPR patience

User Image JBinLB Posted - 5 days ago

$NSPR pure 🗑️

User Image LoyalShark Posted - 5 days ago

$NSPR I would LOVE to call a bottom but this is NOT a bullish chart at this point. Undercut low with lower lows and lower highs. Horrific job by NSPR at creating an expectation of value in the markets. They have been amazing in the trials and creating a base in the medical field which ultimately will lead to increased market value because they will bought out. BUT in creating an expectation of value in the public markets -- they continue to struggle. Doesn't help they are an Isreali company in a war ---- maybe they should work to show the market they are more US based than Isreal? Doesnt help the biotech/medtech indexes are in a correction -- but given the lack of participation in the indexes huge move up from Nov to April...odd they would be part of the draw down when they weren't part of the spike. NSPR's Investor Relations company/Effort absolutely sucks. BEt they didnt make an outgoing call last month. So going to have to base valuations strictly on M&A.

User Image LoyalShark Posted - 6 days ago

$NSPR So whats your thoughts on what InspireMD worth in a buyout?? Who buys them? They will be bought out.

User Image LoyalShark Posted - 6 days ago

$NSPR Dont you love it when $20,000 worth of trades moves the market cap of NSPR down by $10,400,000 TEN MILLION FOUR HUNDRED THOUSAND drop in maret cap on $20,000 worth of trading volume. SHOWS how big a of a POS IR firm InspireMD has. They have totally failed to create a following in the stock or an expectation of value for the company. Really tired of the Investor Relations Incompetence at NSPR. LOVE this opportnuity but have to admit they SUCK at being a public company. They have failed every investor at this point.

User Image TrkDvr Posted - 6 days ago

$NSPR These guys have definitely stepped up their promotional activity. Shane Gleason is by far the best presenter who realizes that the vast majority of investors are not interventionalist.

User Image GiveHerTheDD Posted - 6 days ago

$NSPR New study posted to Inspire's website (but published December 2023): https://pubmed.ncbi.nlm.nih.gov/38385840/ "Conclusions: Meta-analytic integration of available clinical data indicates: 1) reduction in stroke but increased restenosis rate with Casper/Roadsaver, and 2) reduction in both stroke and restenosis with CGuard MicroNET-covered stent against contemporary CEA outcomes at 30 days and 12 months used as a reference." Other note: "Twelve-month Gore stent outcomes were overall inferior to surgery." lol Gore, pls buy us.

User Image JBinLB Posted - 1 week ago

$NSPR not even loyal sharks pumps are keeping us afloat

User Image JBinLB Posted - 1 week ago

$NSPR huge turd here

User Image LoyalShark Posted - 1 week ago

$GNS $NSPR $QRTEA Its not about the cmpanies today. Its about the microcap mkt . CXRSPMC1 microcap index is off 9% in last 11 days. Keep saying Microcaps will have their day but thinking that will only happen after Bidens inflation is finally squelched. There will be better days ahead.

User Image LoyalShark Posted - 1 week ago

$NSPR $SILK $MDT $JNJ will have to buy NSPR or order from them. NO ONE wants a 2nd ..3rd in class stent in them. InspireMD (NSPR) The BEST idea in MedTech PERIOD. No debt. Trial results end of May. Already announced the 30 day results and they were FREAKEN STELLAR - 1st in class by a LOT. OVER 50,000 stents already placed. HISTORIC EXPANDED CMS (medicare/medicaid) coverage Oct 2024 opens HUGE push towards stenting over endarterectomy (cut and pasting arteries) $17 mil milestone payment after May results. The whose who of biotech are in the stock. HEAVY INSTITUTIONAL OWNERSHIP for a microcap. I like NSPR. A lot.

User Image GiveHerTheDD Posted - 1 week ago

$NSPR The last time this traded tight, sideways, and no action for a month, we rallied 300%. Something has to be happening besides the FDA trial wrapping up, or what the hell is 99% of their workforce doing?

User Image GiveHerTheDD Posted - 1 week ago

$NSPR watchlist entirely red except for this on decent volme 👀

User Image LoyalShark Posted - 1 week ago

$NSPR Time to educate the world on what this company has and the opportunity in front of them. This pitiful valuation becomes unsustainable with understanding and awareness.

User Image Capital_Gains_X Posted - 1 week ago

$NSPR started buying this at $12 many moons ago... Was a good value then. It's a great value now!

Analyst Ratings
Piper Sandler Overweight Nov 2, 23
Piper Sandler Overweight Jun 12, 23
National Alliance Securities Buy May 17, 23
Alliance Global Partners Buy Mar 31, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
ROUBIN GARY S Director Director Aug 18 Buy 1.909 35,500 67,770 164,194 08/22/22
Stuka Paul Director Director Nov 29 Buy 3.55 21,549 76,499 61,497 11/30/21
Stuka Paul Director Director Nov 22 Buy 3.54 20,392 72,188 20,420 11/23/21